Share-based Payment Arrangement, Expense of Altimmune, Inc. from 31 Dec 2010 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Altimmune, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2010 to 30 Sep 2025.
  • Altimmune, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $3,554,000, a 15% increase year-over-year.
  • Altimmune, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $14,489,000, a 7.3% increase year-over-year.
  • Altimmune, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $14,393,000, a 35% increase from 2023.
  • Altimmune, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $10,640,000, a 31% increase from 2022.
  • Altimmune, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $8,101,000, a 47% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Altimmune, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $14,489,000 $3,554,000 +$476,000 +15% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $14,013,000 $3,566,000 -$745,000 -17% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $14,758,000 $4,015,000 +$365,000 +10% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $14,393,000 $3,354,000 +$885,000 +36% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 $13,508,000 $3,078,000 +$368,000 +14% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $13,140,000 $4,311,000 +$1,525,000 +55% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $11,615,000 $3,650,000 +$975,000 +36% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $10,640,000 $2,469,000 -$1,453,967 -37% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $12,093,967 $2,710,000 +$582,000 +27% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $11,511,967 $2,786,000 +$738,000 +36% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $10,773,967 $2,675,000 +$2,672,967 +131479% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $8,101,000 $3,922,967 +$1,387,185 +55% 01 Oct 2022 31 Dec 2022 10-K 27 Mar 2024 2023 FY
Q3 2022 $6,713,815 $2,128,000 +$631,000 +42% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $6,082,815 $2,048,000 +$563,000 +38% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $5,519,815 $2,033 +$815 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $5,519,000 $2,535,782 +$1,825,296 +257% 01 Oct 2021 31 Dec 2021 10-K 28 Feb 2023 2022 FY
Q3 2021 $3,693,704 $1,497,000 +$176,911 +13% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $3,516,793 $1,485,000 +$1,154,490 +349% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $2,362,303 $1,218* -$213,703 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q4 2020 $2,576,006 $710,486 +$431,516 +155% 01 Oct 2020 31 Dec 2020 10-K 15 Mar 2022 2021 FY
Q3 2020 $2,144,490 $1,320,089 +$1,032,314 +359% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $1,112,176 $330,510 +$40,738 +14% 01 Apr 2020 30 Jun 2020 10-Q 10 Aug 2021 2021 Q2
Q1 2020 $1,071,438 $214,921 -$192,793 -47% 01 Jan 2020 31 Mar 2020 10-Q 17 May 2021 2021 Q1
Q4 2019 $1,264,231 $278,970 +$210,148 +305% 01 Oct 2019 31 Dec 2019 10-K 25 Feb 2021 2020 FY
Q3 2019 $1,054,083 $287,775 +$192,184 +201% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020 2020 Q3
Q2 2019 $861,899 $289,772 +$37,646 +15% 01 Apr 2019 30 Jun 2019 10-Q 11 Aug 2020 2020 Q2
Q1 2019 $824,253 $407,714 +$51,005 +14% 01 Jan 2019 31 Mar 2019 10-Q 13 May 2020 2020 Q1
Q4 2018 $773,248 $68,822 -$237,610 -78% 01 Oct 2018 31 Dec 2018 10-K 27 Mar 2020 2019 FY
Q3 2018 $1,010,858 $95,591 -$357,446 -79% 01 Jul 2018 30 Sep 2018 10-Q 13 Nov 2019 2019 Q3
Q2 2018 $1,368,304 $252,126 -$86,861 -26% 01 Apr 2018 30 Jun 2018 10-Q 13 Aug 2019 2019 Q2
Q1 2018 $1,455,165 $356,709 +$11,673 +3.4% 01 Jan 2018 31 Mar 2018 10-Q 14 May 2019 2019 Q1
Q4 2017 $1,443,492 $306,432 -$54,568 -15% 01 Oct 2017 31 Dec 2017 10-K 01 Apr 2019 2018 FY
Q3 2017 $1,498,060 $453,037 +$257,981 +132% 01 Jul 2017 30 Sep 2017 10-Q 13 Nov 2018 2018 Q3
Q2 2017 $1,240,079 $338,987 +$111,604 +49% 01 Apr 2017 30 Jun 2017 10-Q 14 Aug 2018 2018 Q2
Q1 2017 $1,128,475 $345,036 +$163,110 +90% 01 Jan 2017 31 Mar 2017 10-Q 15 May 2018 2018 Q1
Q4 2016 $965,365 $361,000 +$174,971 +94% 01 Oct 2016 31 Dec 2016 10-K 02 Apr 2018 2017 FY
Q3 2016 $790,394 $195,056 +$101,299 +108% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017 2017 Q3
Q2 2016 $689,095 $227,383 +$93,779 +70% 01 Apr 2016 30 Jun 2016 10-Q 14 Aug 2017 2017 Q2
Q1 2016 $595,316 $181,926 -$17,701 -8.9% 01 Jan 2016 31 Mar 2016 10-Q 03 May 2017 2017 Q1
Q4 2015 $613,017 $186,029 -$296,915 -61% 01 Oct 2015 31 Dec 2015 10-K 14 Mar 2017 2016 FY
Q3 2015 $909,932 $93,757 -$186,963 -67% 01 Jul 2015 30 Sep 2015 10-Q 04 Nov 2016 2016 Q3
Q2 2015 $1,096,895 $133,604 -$229,501 -63% 01 Apr 2015 30 Jun 2015 10-Q 04 Aug 2016 2016 Q2
Q1 2015 $1,326,396 $199,627 -$329,251 -62% 01 Jan 2015 31 Mar 2015 10-Q 09 May 2016 2016 Q1
Q4 2014 $1,655,647 $482,944 +$77,489 +19% 01 Oct 2014 31 Dec 2014 10-K 14 Mar 2017 2016 FY
Q3 2014 $1,578,158 $280,720 -$23,952 -7.9% 01 Jul 2014 30 Sep 2014 10-Q 06 Nov 2015 2015 Q3
Q2 2014 $1,602,110 $363,105 +$39,097 +12% 01 Apr 2014 30 Jun 2014 10-Q 05 Aug 2015 2015 Q2
Q1 2014 $1,563,013 $528,878 +$200,297 +61% 01 Jan 2014 31 Mar 2014 10-Q 07 May 2015 2015 Q1
Q4 2013 $1,362,716 $405,455 +$11,266 +2.9% 01 Oct 2013 31 Dec 2013 10-K 11 Mar 2016 2015 FY
Q3 2013 $1,351,450 $304,672 -$134,533 -31% 01 Jul 2013 30 Sep 2013 10-Q 06 Nov 2014 2014 Q3
Q2 2013 $1,485,983 $324,008 -$188,033 -37% 01 Apr 2013 30 Jun 2013 10-Q 05 Aug 2014 2014 Q2
Q1 2013 $1,674,016 $328,581 -$220,083 -40% 01 Jan 2013 31 Mar 2013 10-Q 08 May 2014 2014 Q1
Q4 2012 $1,894,099 $394,189 01 Oct 2012 31 Dec 2012 10-K 11 Mar 2015 2014 FY
Q3 2012 $439,205 -$186,886 -30% 01 Jul 2012 30 Sep 2012 10-Q 07 Nov 2013 2013 Q3
Q2 2012 $512,041 -$32,659 -6% 31 Mar 2012 30 Jun 2012 10-Q 07 Aug 2012 2012 Q2
Q1 2012 $548,664 01 Jan 2012 31 Mar 2012 10-Q 08 May 2013 2013 Q1
Q3 2011 $626,091 01 Jul 2011 30 Sep 2011 10-Q 06 Nov 2012 2012 Q3
Q2 2011 $544,700 01 Apr 2011 30 Jun 2011 10-Q 07 Aug 2012 2012 Q2

Altimmune, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $14,393,000 +$3,753,000 +35% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 $10,640,000 +$2,539,000 +31% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $8,101,000 +$2,582,000 +47% 01 Jan 2022 31 Dec 2022 10-K 27 Mar 2024 2023 FY
2021 $5,519,000 +$2,942,994 +114% 01 Jan 2021 31 Dec 2021 10-K 28 Feb 2023 2022 FY
2020 $2,576,006 +$1,311,775 +104% 01 Jan 2020 31 Dec 2020 10-K 15 Mar 2022 2021 FY
2019 $1,264,231 +$490,983 +63% 01 Jan 2019 31 Dec 2019 10-K 25 Feb 2021 2020 FY
2018 $773,248 -$670,244 -46% 01 Jan 2018 31 Dec 2018 10-K 27 Mar 2020 2019 FY
2017 $1,443,492 +$478,127 +50% 01 Jan 2017 31 Dec 2017 10-K 01 Apr 2019 2018 FY
2016 $965,365 +$352,348 +57% 01 Jan 2016 31 Dec 2016 10-K 02 Apr 2018 2017 FY
2015 $613,017 -$1,042,630 -63% 01 Jan 2015 31 Dec 2015 10-K 14 Mar 2017 2016 FY
2014 $1,655,647 +$292,931 +21% 01 Jan 2014 31 Dec 2014 10-K 14 Mar 2017 2016 FY
2013 $1,362,716 -$531,383 -28% 01 Jan 2013 31 Dec 2013 10-K 11 Mar 2016 2015 FY
2012 $1,894,099 -$671,862 -26% 01 Jan 2012 31 Dec 2012 10-K 11 Mar 2015 2014 FY
2011 $2,565,961 +$52,802 +2.1% 01 Jan 2011 31 Dec 2011 10-K 11 Mar 2014 2013 FY
2010 $2,513,159 01 Jan 2010 31 Dec 2010 10-K 14 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.